Product Description
Triclabendazole, a benzimidazole derivative, has been routinely used since 1983 in veterinary medicine to control infections with Fasciola spp. in domestic herbivorous animals. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16307491/)
Mechanisms of Action: Tubulin Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Dominican Republic | Egypt | France | India | Korea | Malaysia | Pakistan | Slovenia | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Fascioliasis
Known Adverse Events: Abdominal Pain | Chest Pain | Headache | Pain Unspecified | Hyperhidrosis | Urticaria | Musculoskeletal Pain | Diarrhea
Company: Molecular Partners
Company Location: Z?RICH-SCHLIEREN V8 8952
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Fascioliasis
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 6 Years of Age or Older | P4 |
Recruiting |
Fascioliasis |
2026-03-18 |
|
| MP0274-CP101 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2021-12-13 |
44% |
| NCT01931085 | N/A |
No longer available |
Other |
None |